無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

欧州のヒアルロン酸 (HA) 関節内補充療法市場

Europe Market Report for Hyaluronic Acid Viscosupplementation 2017 - MedCore

発行 iData Research Inc. 商品コード 524559
出版日 ページ情報 英文 494 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.02円で換算しております。

※ Single Userライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
認証されたPC上のみでの閲覧となっております。

Back to Top
欧州のヒアルロン酸 (HA) 関節内補充療法市場 Europe Market Report for Hyaluronic Acid Viscosupplementation 2017 - MedCore
出版日: 2017年06月01日 ページ情報: 英文 494 Pages
概要

当レポートでは、欧州のヒアルロン酸 (HA) 関節内補充療法市場について調査分析し、市場概要、国別プロファイル、促進要因・阻害要因、競合分析など、体系的な情報を提供しています。

エグゼクティブサマリー

欧州の整形外科用バイオマテリアル市場:概要

競合分析

市場動向

市場の発展

対象市場

主な調査アップデート

バージョン履歴

第1章 調査手法

第2章 疾患の概要

  • 基本構造
  • 疾患の病状・障害
  • 患者の人口統計

第3章 製品の評価

  • 製品ポートフォリオ
  • 規制問題とリコール
  • 臨床試験

第4章 国別プロファイル

  • イントロダクション
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ベネルクス諸国
  • 北欧諸国
  • オーストリア
  • スイス
  • ポルトガル

第5章 ヒアルロン酸 (HA) 関節内補充療法市場

  • イントロダクション
  • 市場概要
  • 市場分析と予測
  • 促進要因・阻害要因
    • 市場促進要因
    • 市場阻害要因
  • 競合市場シェア分析

略語

付録

目次
Product Code: iDATA_EUOB17_MC_HA

Osteoarthritis is a condition marked by the degeneration of bone joints and cartilage. Patients who suffer from osteoarthritis experience acute joint pain, tenderness, stiffness, creaking, locking of the joints and inflammation. These symptoms are caused by the degeneration of joint cartilage, subchondral bone and synovial fluid, specifically the polysaccharide hyaluronate. Cartilage and synovial fluid are important for absorbing stress and cushioning joints during normal activity. Progressive deterioration of cartilage and an overactive immune response may also lead to muscle atrophy and chronic disability. Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan that is naturally present in the human body. It is mainly concentrated in fluids in the joints. Its function is to provide cushioning for joints. Individuals who suffer from osteoarthritis are deficient in these fluids. One of the treatment options for these patients is HA viscosupplementation injections.

General Report Contents:

  • Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
  • Market Drivers & Limiters for each chapter segment
  • Competitive Analysis for each chapter segment
  • Section on recent mergers & acquisitions

Single-Injection Products

Single-injection products are the fastest growing products on the market. As per their name, they require only a single-injection per course of treatment. They are less popular in regions like Italy and Germany, where the costs of the three- and five-injection treatments are relatively low.

Two-Injection Products

Two-injection products are the newest products on this market. As per their name, they require only two-injection per course of treatment.

Three-Injection Cycle Products

Three-injection cycle products are administered once per week for three weeks. These products are generally more popular with patients than their five-injection cycle counterparts, mainly because they require fewer visits to a doctor's office for the administration of the product. However, a number of products can be used in either three- or five-injection treatments.

Five-Injection Cycle Products

Five-injection cycle products are administered once per week for five weeks. The therapeutic effects generally become apparent to the patients near the end of the therapy cycle, and will last for up to six months. Five-injection cycle is particularly popular in countries where there is a monetary incentive per patient visits for doctors. This has the effect of making the five-injection cycle products more popular with doctors, as the profit per course of treatment is higher.

TABLE OF CONTENTS

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY

EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW

COMPETITIVE ANALYSIS

MARKET TRENDS

MARKET DEVELOPMENTS

MARKETS INCLUDED

KEY REPORT UPDATES

VERSION HISTORY

RESEARCH METHODOLOGY

  • 1.1. RESEARCH SCOPE
  • 1.2. IDATA'S 9-STEP METHODOLOGY
    • Step 1: Project Initiation & Team Selection
    • Step 2: Prepare Data Systems and Perform Secondary Research
    • Step 3: Preparation for Interviews & Questionnaire Design
    • Step 4: Performing Primary Research
    • Step 5: Research Analysis: Establishing Baseline Estimates
    • Step 6: Market Forecast and Analysis
    • Step 7: Identify Strategic Opportunities
    • Step 8: Final Review and Market Release
    • Step 9: Customer Feedback and Market Monitoring

DISEASE OVERVIEW

  • 2.1. BASIC ANATOMY
    • 2.1.1. Osteology and Musculoskeletal System
  • 2.2. DISEASE PATHOLOGY AND DISORDERS
    • 2.2.1. General Diagnostic
    • 2.2.2. Osteoporosis
    • 2.2.3. Osteoarthritis
    • 2.2.4. Indication for Bone Graft Procedure
    • 2.2.5. Indication for Cartilage Repair
    • 2.2.6. Degenerative Disc Disease
  • 2.3. PATIENT DEMOGRAPHICS
    • 2.3.1. General Statistics

PRODUCT ASSESSMENT

  • 3.1. PRODUCT PORTFOLIOS
    • 3.1.1. Hyaluronic Acid Viscosupplementation
  • 3.2. REGULATORY ISSUES AND RECALLS
    • 3.2.1. Hyaluronic Acid Viscosupplementation
  • 3.3. CLINICAL TRIALS
    • 3.3.1. Hyaluronic Acid Viscosupplementation

COUNTRY PROFILES

  • 4.1. INTRODUCTION
    • 4.1.1. Population
    • 4.1.2. GDP Per Capita
    • 4.1.3. Price Index
  • 4.2. GERMANY
  • 4.3. FRANCE
  • 4.4. UNITED KINGDOM
  • 4.5. ITALY
  • 4.6. SPAIN
  • 4.7. BENELUX
  • 4.8. SCANDINAVIA
  • 4.9. AUSTRIA
  • 4.10. SWITZERLAND
  • 4.11. PORTUGAL

HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

  • 5.1. INTRODUCTION
    • 5.1.1. Benefits of Viscosupplementation
    • 5.1.2. Synovial Fluid
    • 5.1.3. Treatment Types
  • 5.2. MARKET OVERVIEW
  • 5.3. MARKET ANALYSIS AND FORECAST
    • 5.3.1. Total Hyaluronic Acid Viscosupplementation Market
      • 5.3.1.1. Single-Injection Market
      • 5.3.1.2. Three-Injection Market
      • 5.3.1.3. Five-Injection Market
  • 5.4. DRIVERS AND LIMITERS
    • 5.4.1. Market Drivers
    • 5.4.2. Market Limiters
  • 5.5. COMPETITIVE MARKET SHARE ANALYSIS

ABBREVIATIONS

APPENDIX: COMPANY PRESS RELEASES

LIST OF CHARTS

  • Chart 1 1: Orthopedic Biomaterials Market by Segment, Europe, 2013 - 2023
  • Chart 1 2: Orthopedic Biomaterials Market Overview, Europe, 2016 & 2023
  • Chart 4 1: Country Profile, Germany, 2016
  • Chart 4 2: Country Profile, France, 2016
  • Chart 4 3: Country Profile, United Kingdom, 2016
  • Chart 4 4: Country Profile, Italy, 2016
  • Chart 4 5: Country Profile, Spain, 2016
  • Chart 4 6: Country Profile, Benelux, 2016
  • Chart 4 7: Country Profile, Scandinavia, 2016
  • Chart 4 8: Country Profile, Austria, 2016
  • Chart 4 9: Country Profile, Switzerland, 2016
  • Chart 4 10: Country Profile, Portugal, 2016
  • Chart 5 1: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2013 - 2023
  • Chart 5 2: Hyaluronic Acid Viscosupplementation Market Breakdown, Europe, 2016
  • Chart 5 3: Hyaluronic Acid Viscosupplementation Market Breakdown, Europe, 2023
  • Chart 5 4: Total Hyaluronic Acid Viscosupplementation Market, Europe, 2013 - 2023
  • Chart 5 5: Single-Injection Market, Europe, 2013 - 2023
  • Chart 5 6: Three-Injection Market, Europe, 2013 - 2023
  • Chart 5 7: Five-Injection Market, Europe, 2013 - 2023
  • Chart 5 8: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Europe, 2016

LIST OF FIGURES

  • Figure 1 1: Orthopedic Biomaterials Market Share Ranking by Segment, Europe, 2016
  • Figure 1 2: Companies Researched in this Report, Europe, 2016
  • Figure 1 3: Factors Impacting the Orthopedic Biomaterials Market by Segment, Europe
  • Figure 1 4: Recent Events in the Orthopedic Biomaterials Market, Europe, 2015 - 2016
  • Figure 1 5: Orthopedic Biomaterials Markets Covered, Europe, 2016 (1 of 2)
  • Figure 1 6: Orthopedic Biomaterials Markets Covered, Europe, 2016 (2 of 2)
  • Figure 1 7: Key Report Updates
  • Figure 1 8: Version History
  • Figure 3 1: Hyaluronic Acid Viscosupplementationby Products by Company
  • Figure 3 2: Class 3 Device Recall Euflexxa (1 sodium hyaluronate)
  • Figure 3 3: Trial Comparing Botulin Toxin Versus Hyaluronic Acid by Intra-articular Injection (GOTOX)
  • Figure 3 4: Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Intra-articular Injections of HA (ViscOA)
  • Figure 3 5: Platelet-rich Plasma vs. Hyaluronic Acid for Glenohumeral Osteoarthritis
  • Figure 3 6: Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid (PNHA1401)
  • Figure 3 7: To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection
  • Figure 3 8: Platelet-rich Plasma vs Viscosupplementation in the Treatment of Knee Articular Degenerative Pathology (PRP)
  • Figure 3 9: Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy
  • Figure 3 10: Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the Knee
  • Figure 5 1: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2013 - 2023 (€M)
  • Figure 5 2: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2013 - 2023 (US$M)
  • Figure 5 3: Total Hyaluronic Acid Viscosupplementation Market, Europe, 2013 - 2023
  • Figure 5 4: Units Sold by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2013 - 2023
  • Figure 5 5: Average Selling Price by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2013 - 2023 (€)
  • Figure 5 6: Average Selling Price by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2013 - 2023 (US$)
  • Figure 5 7: Market Value by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2013 - 2023 (€M)
  • Figure 5 8: Market Value by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2013 - 2023 (US$M)
  • Figure 5 9: Single-Injection Market, Europe, 2013 - 2023
  • Figure 5 10: Units Sold by Country, Single-Injection Market, Europe, 2013 - 2023
  • Figure 5 11: Average Selling Price by Country, Single-Injection Market, Europe, 2013 - 2023 (€)
  • Figure 5 12: Average Selling Price by Country, Single-Injection Market, Europe, 2013 - 2023 (US$)
  • Figure 5 13: Market Value by Country, Single-Injection Market, Europe, 2013 - 2023 (€M)
  • Figure 5 14: Market Value by Country, Single-Injection Market, Europe, 2013 - 2023 (US$M)
  • Figure 5 15: Three-Injection Market, Europe, 2013 - 2023
  • Figure 5 16: Units Sold by Country, Three-Injection Market, Europe, 2013 - 2023
  • Figure 5 17: Average Selling Price by Country, Three-Injection Market, Europe, 2013 - 2023 (€)
  • Figure 5 18: Average Selling Price by Country, Three-Injection Market, Europe, 2013 - 2023 (US$)
  • Figure 5 19: Market Value by Country, Three-Injection Market, Europe, 2013 - 2023 (€M)
  • Figure 5 20: Market Value by Country, Three-Injection Market, Europe, 2013 - 2023 (US$M)
  • Figure 5 21: Five-Injection Market, Europe, 2013 - 2023
  • Figure 5 22: Units Sold by Country, Five-Injection Market, Europe, 2013 - 2023
  • Figure 5 23: Average Selling Price by Country, Five-Injection Market, Europe, 2013 - 2023 (€)
  • Figure 5 24: Average Selling Price by Country, Five-Injection Market, Europe, 2013 - 2023 (US$)
  • Figure 5 25: Market Value by Country, Five-Injection Market, Europe, 2013 - 2023 (€M)
  • Figure 5 26: Market Value by Country, Five-Injection Market, Europe, 2013 - 2023 (US$M)
  • Figure 5 27: Drivers and Limiters, Hyaluronic Acid Viscosupplementation Market, Europe, 2016
  • Figure 5 28: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Europe, 2016
  • Figure 7 1: Press Release Summary
Back to Top